BioMarin Announces BioMarin RareConnections(TM) Rebranding and Consolidating BioMarin’s Comprehensive Support and Services for Eligible Rare Disease Patients

SAN RAFAEL, Calif., Feb. 29, 2016 -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the launch of BioMarin RareConnections^TM, rebranding its patient-focused offering formally known as the BioMarin Patient and Physician Support (BPPS). For over 10 years, BioMarin has been a leader in designing and implementing multiple separate service offerings to support our patients.  With the launch of BioMarin RareConnections, it now provides them under one expanded program, which includes clinical support for eligible patients throughout treatment and assistance to gain and maintain access to BioMarin’s innovative therapies.

BioMarin RareConnections offers personalized assistance to patients in the United States, who have been prescribed or are considering a BioMarin therapy for Morquio A, MPS VI and phenylketonuria (PKU), and their caregivers.  While specific services will vary by medication, BioMarin RareConnections support includes access to dedicated case managers and clinical coordinators, as well as help securing insurance coverage and/or financial assistance. Additional services may include coordination of medication deliveries and disease and product education.

“Patients and their families battling rare conditions face uncommon challenges. As a leader in the community, it is our responsibility to provide unparalleled support to help ensure our patients, who are eligible for BioMarin approved therapies, have access to, and are connected with, the exceptional care they deserve,” said Jeff Ajer, Chief Commercial Officer of BioMarin. “We are proud that BioMarin RareConnections will house all of our support services in one area to help us serve as a trusted partner in care.”

To learn more about BioMarin RareConnections, call 1-866-906-6100 or email [email protected].

About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.

Contact:
Investors: 			
Traci McCarty 			
BioMarin Pharmaceutical Inc. 
(415) 455-7558			

Media:
Debra Charlesworth
BioMarin Pharmaceutical Inc.
(415) 455-7451